Prosecution Insights
Last updated: November 04, 2026

Apix Biosciences

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Apix Biosciences is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, indicating that the company's pending research covers different specialized fields within the sector. The involvement of multiple art units suggests a technical footprint that spans several areas of review.

Prosecution is handled by a pair of distinct examiners. WILLIAMS, EMMALEE RAE is the busiest examiner, responsible for 1 pending office action. With two distinct examiners for the pending office actions, each application is being reviewed independently. This means that the practitioner must manage separate prosecution tracks, each tailored to the specific examiner and art unit involved. The distribution among the 2 distinct examiners ensures that the outcome of one pending office action does not necessarily influence the other.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (50%)
1
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
Multi-statute (no §101)1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WILLIAMS, EMMALEE RAE 1 25.0% +100.0%
DIVIESTI, KARLA ISOBEL 1 3.2% +16.7%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18693323 PROANTHOCYANIDINS (CONDENSED TANNINS) AS INVERTEBRATE NUTRIENT DIVIESTI, KARLA ISOBEL 36d
18710789 STEROL PRODUCTION IN YEAST WILLIAMS, EMMALEE RAE —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18693323 PROANTHOCYANIDINS (CONDENSED TANNINS) AS INVERTEBRATE NUTRIENT DIVIESTI, KARLA ISOBEL 36d
18710789 STEROL PRODUCTION IN YEAST WILLIAMS, EMMALEE RAE —

Top Art Units

Art UnitApps
1653 1
1792 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18710789 STEROL PRODUCTION IN YEAST WILLIAMS, EMMALEE RAE 1653 §103§112 Non-Final OA — Pending May 16, 2024
18693323 PROANTHOCYANIDINS (CONDENSED TANNINS) AS INVERTEBRATE NUTRIENT DIVIESTI, KARLA ISOBEL 1792 §103 Final Rejection 36d Pending Mar 19, 2024

Managing Apix Biosciences's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Apix Biosciences have?

Apix Biosciences has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Apix Biosciences applications?

Emmalee Rae Williams has the most, with 1 of Apix Biosciences's pending office actions.

What technology area are Apix Biosciences's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month